List of VMAT2 inhibitors - Drugs.com
VMAT2 inhibitors (vesicular monoamine transporter-2 inhibitors) are used to treat movement disorders such as Huntington’s disease or tardive dyskinesia.
Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors
2019年4月2日 · Valbenazine (val ben' a zeen) is an inhibitor of synaptic vesicular monoamine transporter 2 (VMAT2), the inhibition of which causes a depletion of neuroactive monoamines (serotonin, norepinephrine and particularly dopamine) in nerve terminals.
VMAT2 Inhibitors: Drug Class, Uses, Side Effects, Drug Names
Vesicular monoamine transporter 2 (VMAT2) inhibitors are drugs used for treating uncontrolled, involuntary movements associated with Huntington’s disease, tardive dyskinesia, or Tourette’s syndrome. Learn about side effects, usage, and drug list.
Reversible Vesicular Monoamine Transporter 2 (VMAT2) inhibitors, a transporter that regulates monoamine uptake from the cytoplasm to the synaptic vesicle for storage & release
Valbenazine: Uses, Dosage, Side Effects, Warnings - Drugs.com
2024年5月3日 · Valbenazine is a type of drug called a VMAT2 (vesicular monoamine transporter 2) inhibitor. It is thought to work by preventing the release of dopamine from small structures (vesicles) within dopamine-producing nerve cells, which reduces extra dopamine signaling in …
Tetrabenazine, the first VMAT-2 inhibitor, was approved in 2008 for Huntington’s chorea and is used off-label for the treatment of TD. Deutetrabenazine and valbenazine were FDA approved in 2017. Currently, deutetrabenazine, tetrabenazine, …
The vesicular monoamine transporter 2: an underexplored ...
Novel VMAT2 inhibitors that are specific to each monoamine (i.e. a serotonergic specific VMAT2 inhibitor) may have improved efficacy for the treatment of hypermonoaminergic disorders. Additionally, direct or indirect enhancers of VMAT2 may prove highly beneficial in the treatment of hypomonoaminergic disease, such as PD.